MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- TORRENT PHARMA - ACTAVIS (US)
TORRENT PHARMA vs ACTAVIS (US) - Comparison Results
TORRENT PHARMA Change
Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 TORRENT PHARMA  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| TORRENT PHARMA Mar-19 |
ACTAVIS Dec-18 |
TORRENT PHARMA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,964 | 14,449 | - | |
| Low | Rs | 1,245 | 9,692 | - | |
| Sales per share (Unadj.) | Rs | 453.4 | 3,544.2 | - | |
| Earnings per share (Unadj.) | Rs | 25.8 | -1,141.6 | - | |
| Cash flow per share (Unadj.) | Rs | 62.3 | 373.5 | - | |
| Dividends per share (Unadj.) | Rs | 17.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.1 | 0 | - | |
| Book value per share (Unadj.) | Rs | 279.2 | 14,618.3 | - | |
| Shares outstanding (eoy) | m | 169.22 | 332.60 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.5 | 3.4 | 103.9% | |
| Avg P/E ratio | x | 62.2 | -10.6 | -588.6% | |
| P/CF ratio (eoy) | x | 25.8 | 32.3 | 79.7% | |
| Price / Book Value ratio | x | 5.7 | 0.8 | 696.0% | |
| Dividend payout | % | 65.9 | 0 | - | |
| Avg Mkt Cap | Rs m | 271,513 | 4,014,617 | 6.8% | |
| No. of employees | `000 | 13.6 | 16.9 | 80.5% | |
| Total wages/salary | Rs m | 14,038 | 0 | - | |
| Avg. sales/employee | Rs Th | 5,642.6 | 69,752.4 | 8.1% | |
| Avg. wages/employee | Rs Th | 1,032.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 320.9 | -22,467.3 | -1.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 76,728 | 1,178,815 | 6.5% | |
| Other income | Rs m | 571 | 22,543 | 2.5% | |
| Total revenues | Rs m | 77,299 | 1,201,358 | 6.4% | |
| Gross profit | Rs m | 19,831 | 30,891 | 64.2% | |
| Depreciation | Rs m | 6,177 | 503,918 | 1.2% | |
| Interest | Rs m | 5,038 | 68,024 | 7.4% | |
| Profit before tax | Rs m | 9,187 | -518,508 | -1.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -3,570 | 132,241 | -2.7% | |
| Tax | Rs m | 1,254 | -6,571 | -19.1% | |
| Profit after tax | Rs m | 4,363 | -379,697 | -1.1% | |
| Gross profit margin | % | 25.8 | 2.6 | 986.3% | |
| Effective tax rate | % | 13.6 | 1.3 | 1,076.7% | |
| Net profit margin | % | 5.7 | -32.2 | -17.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 50,375 | 483,488 | 10.4% | |
| Current liabilities | Rs m | 51,653 | 427,710 | 12.1% | |
| Net working cap to sales | % | -1.7 | 4.7 | -35.2% | |
| Current ratio | x | 1.0 | 1.1 | 86.3% | |
| Inventory Days | Days | 92 | 20 | 470.1% | |
| Debtors Days | Days | 68 | 66 | 103.0% | |
| Net fixed assets | Rs m | 83,648 | 133,435 | 62.7% | |
| Share capital | Rs m | 846 | 0 | - | |
| Net worth | Rs m | 47,244 | 4,862,062 | 1.0% | |
| Long term debt | Rs m | 39,129 | 1,712,108 | 2.3% | |
| Total assets | Rs m | 141,209 | 7,600,510 | 1.9% | |
| Interest coverage | x | 2.8 | -6.6 | -42.6% | |
| Debt to equity ratio | x | 0.8 | 0.4 | 235.2% | |
| Sales to assets ratio | x | 0.5 | 0.2 | 350.3% | |
| Return on assets | % | 6.7 | -4.1 | -162.3% | |
| Return on equity | % | 9.2 | -7.8 | -118.3% | |
| Return on capital | % | 12.3 | -4.8 | -254.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 17,981 | 421,146 | 4.3% | |
| From Investments | Rs m | -2,413 | 231,365 | -1.0% | |
| From Financial Activity | Rs m | -13,145 | -722,813 | 1.8% | |
| Net Cashflow | Rs m | 2,380 | -69,951 | -3.4% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.67 Rs / USD
Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare TORRENT PHARMA With: GLENMARK PHARMA CIPLA DR. DATSONS LABS PROCTER & GAMBLE HEALTH ABBOTT INDIA
Today's Market
Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Related Views On News
TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)
Oct 27, 2020 | Updated on Oct 27, 2020For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)
Jul 31, 2020 | Updated on Jul 31, 2020For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
More Views on NewsMost Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
